METHODS: ONB patients with dural recurrences treated between 2013 and 2022 on a prospective registry were included. Tumor control, survival, and patient-reported quality of life were analyzed.
RESULTS: Fourteen patients with 32 dural lesions were evaluated. Time to dural recurrence was 58.3 months. Thirty lesions (94%) were treated with SBRT to a median dose of 27 Gy in three fractions. Two patients (3 of 32 lesions; 9%) developed in-field radiographic progression, five patients (38%) experienced progression in non-contiguous dura. Two-year local control was 85% (95% CI: 51-96%). There were no >grade 3 acute toxicities and 1 case of late grade 3 brain radionecrosis.
CONCLUSIONS: In this largest study of SBRT reirradiation for ONB dural recurrence to date, high local control rates with minimal toxicity were attainable.
方法:纳入2013年至2022年期间接受前瞻性登记治疗的硬脑膜复发的ONB患者。肿瘤控制,生存,并对患者报告的生活质量进行分析.
结果:评估了14例32个硬脑膜病变的患者。硬膜复发时间为58.3个月。用SBRT治疗30个病变(94%),分三个部分,中位剂量为27Gy。两名患者(32个病灶中的3个;9%)出现了场内放射学进展,5例患者(38%)在非连续硬脑膜出现进展.两年局部控制为85%(95%CI:51-96%)。没有>3级急性毒性和1例晚期3级脑放射性坏死。
结论:在这项迄今为止最大的SBRT再放疗治疗ONB硬膜复发的研究中,可以达到高的局部控制率和最小的毒性。